MTOR and interstitial lung disease: Th17-focused therapy seems to show some promise as there is evidence of two patients, presenting with arthritis, ILD, and follicular bronchiolitis, having significant improvement of pulmonary involvement after treatment with mTOR inhibitor sirolimus.